AstraZeneca’s Imfinzi Gets Pass From FDA Advisors But Future Perioperative Drugs Don’t

 
• By Sarah Karlin-Smith
  
Generate a summary of this article
Listen to this article
Beta

The Oncologic Drugs Advisory Committee urged the FDA not to delay Imfiniz’s perioperative NSCLC indication, while also unanimously pushing for better trial designs in lung cancer and all resectable tumors.

black and white image of doctor with floating lungs above doctor's hands.
The ODAC discussion may have saved AstraZeneca's Imfinizi from a complete response letter. • Source: Shutterstock

A US Food and Drug Administration advisory committee appeared supportive of granting AstraZeneca PLC’s Imfinzi (durvalumab) a supplemental indication for perioperative use in resectable non-small cell lung cancer (NSCLC), despite the agency’s frustration that the sponsor did not demonstrate the full duration of therapy, particularly the post-surgery treatment, is necessary.

Key Takeaways

  • ODAC does not want the FDA to delay AstraZeneca’s Imfinizi approval for perioperative use in NSCLC despite uncertainty about whether patients need the full treatment duration.

However, while AstraZeneca warranted a pass, the Oncologic Drugs Advisory Committee agreed with the FDA that better trial designs should...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By Vibha Sharma

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.